Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure

Roberta S. Azevedo, Guillermo Garcia-Manero, Elias Jabbour, Danielle Hammond, Kelly Chien, Tapan Kadia, Steven Kornblau, Farhad Ravandi, Gautam Borthakur, Naveen Pemmaraju, Hyunsoo Hwang, Xuelin Huang, Heather Schneider, Meghan Meyer, Guillermo Montalban-Bravo

Blood (2025) 146 (Supplement 1): 5645.

https://doi.org/10.1182/blood-2025-5645

Published: 2025

Journal Articles

Ribosome biogenesis and its regulation by the exportin, CSE1L, are targetable vulnerabilities in childhood and young adult Acute Myeloid Leukemia

Grace Egan, Amit Kumar, Veronique Voisin, Rose Hurren, Ali Chegini, Dakai Ling, Geethu Thomas, Yongran Yan, Yue Feng, Nathan Duong, Dilshad Khan, Chaitra Sarathy, Suraj Bansal, Andy Zeng, Fieke Hoff, Steven Kornblau, John Dick, Johann Hitzler, Aaron Schimmer

Blood (2025) 146 (Supplement 1): 1452.

https://doi.org/10.1182/blood-2025-1452

Published: 2025

Journal Articles

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Blood (2025) 146 (Supplement 1): 681.

https://doi.org/10.1182/blood-2025-681

Published: 2025

Journal Articles

Determining sensitivity to FLT3 inhibitors prior to therapy in FLT3 mutant acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Salvador Martinez-Bartolome, James Sorrentino, Mahan Abbasian, Antonius Koller, Samanta Catueno, Brandon Brown, Yihua Qiu, Pilgrim Jackson, Steven Kornblau

Blood (2025) 146 (Supplement 1): 3507.

https://doi.org/10.1182/blood-2025-3507

Published: 2025

Journal Articles

Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Steven Kornblau

Blood (2025) 146 (Supplement 1): 3494.

https://doi.org/10.1182/blood-2025-3494

Published: 2025

Journal Articles

Changing dogma regarding mutation primacy in acute myelogenous leukemia : Protein expression supersedes mutation status

Steven Kornblau, Eduardo de Camargo Magalhaes, Brandon Brown, Samanta Catueno, Yihua Qiu, Courtney DiNardo, Farhad Ravandi

Blood (2025) 146 (Supplement 1): 3492.

https://doi.org/10.1182/blood-2025-3492

Published: 2025

Journal Articles

Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 222.

https://doi.org/10.1182/blood-2025-222

Published: 2025

Journal Articles

High levels of PTPN11 protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Steven Kornblau

Blood (2025) 146 (Supplement 1): 1700.

https://doi.org/10.1182/blood-2025-1700

Published: 2025

Journal Articles

Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome

Blood (2025) 146 (Supplement 1): 997.

https://doi.org/10.1182/blood-2025-997

Published: 2025

Journal Articles

Unidirectional synergy between ferroptosis and apoptosis reveals a novel therapeutic strategy for refractory AML

Blood (2025) 146 (Supplement 1): 5050.

https://doi.org/10.1182/blood-2025-5050

Published: 2025

Journal Articles

Low levels of wilms tumor 1 (WT1) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Steven Kornblau

Blood (2025) 146 (Supplement 1): 5271.

https://doi.org/10.1182/blood-2025-5271

Published: 2025

Journal Articles

Protein levels of isocitrate dehydrogenase 1 and 2 are prognostic and independent of mutation status in acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Ian Bouligny, Abhishek Maiti, Courtney DiNardo, Steven Kornblau

Blood (2025) 146 (Supplement 1): 5270.

https://doi.org/10.1182/blood-2025-5270

Published: 2025

Journal Articles

Low levels of enhancer of zeste homolog 2 (EZH2) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia.

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Mathilde Poplineau, Steven Kornblau

Blood (2025) 146 (Supplement 1): 5259.

https://doi.org/10.1182/blood-2025-5259

Published: 2025

Journal Articles

High protein expression of MDS1 and EVI1 complex locus (MECOM) is prognostically adverse and independent of chromosome 3 rearrangements in acute myelogenous leukemia

Steven Kornblau, Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Abhishek Maiti, Tapan Kadia

Blood (2025) 146 (Supplement 1): 5258.

https://doi.org/10.1182/blood-2025-5258

Published: 2025

Journal Articles

Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia

Vanthana Bharathi, Alexandre Bazinet, Alex Bataller, Naval Daver, Courtney DiNardo, Hussein Abbas, Ian Bouligny, Gautam Borthakur, Fadi Haddad, Naveen Pemmaraju, Steven Kornblau, Wei-Ying Jen, Nicholas Short, Andres Quesada, Guillermo Garcia-Manero, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3405.

https://doi.org/10.1182/blood-2025-3405

Published: 2025

Journal Articles

Protein expression signatures reveal age-specific risk patterns in B-ALL

Samanta Catueno, Yihua Qiu, Gaye Jenkins, Eduardo de Camargo Magalhaes, Brandon Brown, Rebecca Garris, Branko Cuglievan, Elias Jabbour, Nicholas Short, Terzah Horton, Steven Kornblau

Blood (2025) 146 (Supplement 1): 1593.

https://doi.org/10.1182/blood-2025-1593

Published: 2025

Journal Articles

Multiarm Phase I study of the cyclin dependent kinase (CDK4/6) inhibitor palbociclib in combination for patients with relapsed and refractory acute leukemias

Hannah Goulart, Caitlin Rausch, Elias Jabbour, Abhishek Maiti, David McCall, Naval Daver, Nicholas Short, Naveen Pemmaraju, Musa Yilmaz, Danielle Hammond, Steven Kornblau, Ghayas Issa, Branko Cuglievan, Farhad Ravandi, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 5204.

https://doi.org/10.1182/blood-2025-5204

Published: 2025

Journal Articles

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes

Blood (2025) 145 (25): 3015–3029.

https://doi.org/10.1182/blood.2024027244

Published: 2025

Includes: Supplemental data

Journal Articles

Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Elias Jabbour, MD, Kathryn G. Roberts, PhD, Koji Sasaki, MD, Yaqi Zhao, MSc, Chunxu Qu, PhD, Zhaohui Gu, PhD, Nitin Jain, MD, Keyur P. Patel, MBBS, PhD, Farhad Ravandi, MD, Nicholas J. Short, MD, Guillermo Garcia-Manero, MD, Rebecca Garris, MSc, Steven Kornblau, Marina Y Konopleva, MD PhD, Charles G. Mullighan, MBBS, MD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 1641.

https://doi.org/10.1182/blood-2019-126940

Published: 2019

Journal Articles

Proteomic Profiling Reveals Protein Expression Patterns Correlated with Outcome in Acute Promyelocytic Leukemia (APL)

Fieke Hoff, Wendy Hu, MD, Yihua Qiu, Amina Qutub, Steven Kornblau, MD

Blood (2017) 130 (Supplement 1): 5070.

https://doi.org/10.1182/blood.V130.Suppl_1.5070.5070

Published: 2017

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure

Ribosome biogenesis and its regulation by the exportin, CSE1L, are targetable vulnerabilities in childhood and young adult Acute Myeloid Leukemia

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Determining sensitivity to FLT3 inhibitors prior to therapy in FLT3 mutant acute myelogenous leukemia

Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia

Changing dogma regarding mutation primacy in acute myelogenous leukemia : Protein expression supersedes mutation status

Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia

High levels of PTPN11 protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome

Unidirectional synergy between ferroptosis and apoptosis reveals a novel therapeutic strategy for refractory AML

Low levels of wilms tumor 1 (WT1) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

Protein levels of isocitrate dehydrogenase 1 and 2 are prognostic and independent of mutation status in acute myelogenous leukemia

Low levels of enhancer of zeste homolog 2 (EZH2) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia.

High protein expression of MDS1 and EVI1 complex locus (MECOM) is prognostically adverse and independent of chromosome 3 rearrangements in acute myelogenous leukemia

Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia

Protein expression signatures reveal age-specific risk patterns in B-ALL

Multiarm Phase I study of the cyclin dependent kinase (CDK4/6) inhibitor palbociclib in combination for patients with relapsed and refractory acute leukemias

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes

Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Proteomic Profiling Reveals Protein Expression Patterns Correlated with Outcome in Acute Promyelocytic Leukemia (APL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only